Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Qiagen N.V. Common Shares (NY:QGEN)

40.05 +0.03 (+0.07%)
Streaming Delayed Price Updated: 2:18 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Qiagen N.V. Common Shares

< Previous 1 2 3 4 Next >
QIAGEN Launches QIAprep&amp Plasmodium Kit to Strengthen Malaria Research and Surveillance Efforts
From QIAGEN N.V.
Via Business Wire
QIAGEN Announces Form 20-F Annual Report Filing for 2024 Results
From QIAGEN N.V.
Via Business Wire
QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio
From QIAGEN N.V.
Via Business Wire
QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing
From QIAGEN N.V.
Via Business Wire
QIAGEN Strengthens Global Bioinformatics Leadership With New Data Center in Australia/Asia-Pacific Region
From QIAGEN N.V.
Via Business Wire
QIAGEN delivers solid Q4 2024 growth ahead of outlook
From QIAGEN N.V.
Via Business Wire
QIAGEN receives positive court decision reaffirming an important QuantiFERON-TB patent
From QIAGEN N.V.
Via Business Wire
QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $300 Million
From QIAGEN N.V.
Via Business Wire
QIAGEN N.V. to Release Results for Q4 2024 and Hold Webcast
From QIAGEN N.V.
Via Business Wire
QIAGEN to Return Approximately $300 Million to Shareholders Through a Synthetic Share Repurchase
From QIAGEN N.V.
Via Business Wire
QIAGEN Increases QIAcuity Digital PCR High-Order Multiplexing Capabilities to Gain Deeper Insights From Biological Samples
From QIAGEN N.V.
Via Business Wire
QIAGEN secures U.S. clearance for first QIAstat-Dx mini gastrointestinal panel to support year-round outpatient care
From QIAGEN N.V.
Via Business Wire
QIAGEN Supports UK Initiative to Sequence Genomes of 100,000 Newborns With Expert-Curated Genomic Content
From QIAGEN N.V.
Via Business Wire
QIAGEN Launches AI-Extension of Ingenuity Pathway Analysis for Automatic Interpretation of Biological Data
From QIAGEN N.V.
Via Business Wire
QIAGEN Reaches Milestone With Over 1,000 Placements of EZ2 Connect Sample Preparation Instrument, Driving Laboratory Automation
From QIAGEN N.V.
Via Business Wire
QIAGEN Strengthens QIAstat-Dx With New Barcelona Site to Drive Growth in Infectious Diseases and Precision Medicine Testing
From QIAGEN N.V.
Via Business Wire
Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%
From Myriad Genetics, Inc.
Via GlobeNewswire
Strategic Buy Lights Up This Biotech Stock: Time to Invest?
Life sciences company Illumina Inc. (NASDAQ: ILMN) stock surged over 10% following its announcement of the acquisition of Fluent Biosciences. 
Via MarketBeat
QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
From Myriad Genetics, Inc.
Via GlobeNewswire
QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer
From Myriad Genetics, Inc.
Via GlobeNewswire
Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement
From Bio-Rad Laboratories, Inc.
Via Business Wire
QIAGEN Announces Form 20-F Annual Report Filing for 2022 Results
From QIAGEN N.V.
Via Business Wire
QIAGEN and Servier Partner to Develop Companion Diagnostic for Acute Myeloid Leukemia (AML) Therapy Drug
From QIAGEN N.V.
Via Business Wire
QIAGEN and SOPHiA GENETICS Forge Partnership to Combine Strengths in Next-Generation Sequencing
From QIAGEN N.V.
Via Business Wire
QIAGEN’s tuberculosis blood test QuantiFERON-TB Gold Plus gains CE-marking under new EU IVDR framework
From QIAGEN N.V.
Via Business Wire
QIAGEN Exceeds Outlook for Fourth Quarter and Full-Year 2022 With 14% CER Sales Growth in FY 2022 From Non-COVID Product Groups
From QIAGEN N.V.
Via Business Wire
QIAGEN Launches EZ2 Connect MDx Platform for Automated Sample Processing in Diagnostic Labs
From QIAGEN N.V.
Via Business Wire
QIAGEN N.V. to Release Results for Q4 and Full-Year Results 2022 and Hold Webcast
From QIAGEN N.V.
Via Business Wire
QIAGEN Completes Acquisition of Verogen, Strengthening Leadership in Human ID / Forensics With NGS Technologies
From QIAGEN
Via Business Wire
QIAGEN and Helix Launch Exclusive Partnership to Advance Next-Generation Sequencing Companion Diagnostics in Hereditary Diseases
From QIAGEN N.V.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.